Neuren Pharmaceuticals (NURPF) News Today C$8.17 0.00 (0.00%) As of 05/29/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock NURPF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Neuren Pharmaceuticals Updates on Securities Buy-BackMay 27 at 6:05 PM | tipranks.comNeuren Pharmaceuticals AGM: All Resolutions Successfully PassedMay 26, 2025 | tipranks.comNeuren Pharmaceuticals Reports Record Growth and Expands Clinical TrialsMay 26, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Securities Buy-Back ProgramMay 26, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Ongoing Buy-Back ProgramMay 25, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Buy-Back ProgramMay 21, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Securities Buy-BackMay 20, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Daily Buy-Back ActivityMay 18, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Buy-Back ProgramMay 14, 2025 | tipranks.comNeuren Pharmaceuticals Ltd (NURPF)May 13, 2025 | nasdaq.comNeuren Pharmaceuticals Advances Phase 3 Trial for Phelan-McDermid SyndromeMay 13, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramMay 12, 2025 | tipranks.comThursday’s HotCopper Trends: Neuren's sales win, Locksley drills | May 8, 2025May 8, 2025 | msn.comNeuren reports higher Q1 sales for US drugMay 7, 2025 | msn.comNeuren Pharmaceuticals Updates on Buy-back ProgramMay 6, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Buy-Back ProgramMay 5, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Market Buy-Back ProgressMay 4, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Ongoing Share Buy-Back ProgramMay 1, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgressApril 29, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Ongoing Securities Buy-BackApril 28, 2025 | tipranks.comNeuren Pharmaceuticals Releases Online Meeting Guide for ShareholdersApril 23, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgressApril 22, 2025 | tipranks.comNeuren Pharmaceuticals Continues Daily Securities Buy-BackApril 16, 2025 | tipranks.comNeuren Pharmaceuticals Director Increases ShareholdingApril 16, 2025 | tipranks.comLunch Wrap: ASX surges on Washington relief, Neuren rockets and GGE leads small capsApril 15, 2025 | msn.comNeuren Pharmaceuticals Advances Phase 3 Trial for Phelan-McDermid SyndromeApril 13, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramApril 6, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgressApril 3, 2025 | tipranks.comNeuren Pharmaceuticals Releases 2024 Corporate Governance StatementApril 2, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Buy-Back ProgramApril 2, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramApril 1, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Buy-Back ProgramMarch 30, 2025 | tipranks.comNeuren Pharmaceuticals Advances NNZ-2591 for Newborn Brain Injury TreatmentMarch 27, 2025 | tipranks.comNeuren Pharmaceuticals Updates Share Buy-Back ProgressMarch 24, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramMarch 20, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramMarch 19, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Ongoing Share Buy-BackMarch 18, 2025 | msn.comNeuren Pharmaceuticals Updates on Buy-Back ProgramMarch 17, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgressMarch 16, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramMarch 13, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Securities Buy-BackMarch 12, 2025 | tipranks.comNeuren Pharmaceuticals Limited (NURPF) Gets a Buy from Bell PotterMarch 11, 2025 | markets.businessinsider.comNeuren Pharmaceuticals Updates on Securities Buy-Back ProgramMarch 11, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgressMarch 10, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramMarch 9, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramMarch 4, 2025 | tipranks.comHealth Check: Half-price sale as brokers ring the bell on Neuren sharesMarch 4, 2025 | msn.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramMarch 3, 2025 | tipranks.comNeuren Pharmaceuticals Reports Cessation of SecuritiesMarch 3, 2025 | tipranks.comNeuren Pharmaceuticals Sees Robust Growth in DAYBUE SalesFebruary 26, 2025 | tipranks.com Get Neuren Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NURPF and its competitors with MarketBeat's FREE daily newsletter. Email Address NURPF Media Mentions By Week NURPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NURPF News Sentiment▼0.010.87▲Average Medical News Sentiment NURPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NURPF Articles This Week▼51▲NURPF Articles Average Week Get Neuren Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NURPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Ascentage Pharma Group International News Today Ascletis Pharma News Today Avacta Group News Today Awakn Life Sciences News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NURPF) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NURPF Stock Free NURPF Stock Alerts